Reach out to the Acquis team
Over the next decade, biopharma success will be determined not by the most ambitious science or the largest balance sheets, but by leadership — specifically, by companies that can navigate the industry's bifurcation and develop fluency in the Alliance Economy. Others will likely face acquisition or marginalization.
Read More
Leading PE firms are using AI to eliminate data latency, reduce churn, and transform quarterly reviews into continuous portfolio intelligence.
Read More
We are entering what can best be described as the Alliance Economy, an operating model defined not by linear development pipelines, but by an ecosystem of interdependent players working together to navigate the new biopharma reality.
Read More
Over the next decade, biopharma success will be determined not by the most ambitious science or the largest balance sheets, but by leadership — specifically, by companies that can navigate the industry's bifurcation and develop fluency in the Alliance Economy. Others will likely face acquisition or marginalization.
Read More
Leading PE firms are using AI to eliminate data latency, reduce churn, and transform quarterly reviews into continuous portfolio intelligence.
Read More
We are entering what can best be described as the Alliance Economy, an operating model defined not by linear development pipelines, but by an ecosystem of interdependent players working together to navigate the new biopharma reality.
Read More
